位置:首页 > 产品库 > Difluprednate
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Difluprednate
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Difluprednate图片
CAS NO:23674-86-4
包装与价格:
包装价格(元)
25 mg询价
50 mg询价
100 mg询价
200 mg询价
1 mL*10 mM(in DMSO)询价

Myser
Epitopic
二氟孕甾丁酯
CM 9155
Difluprednate 是一种可用于术后眼睛疼痛和炎症的皮质类固醇。

产品描述

Difluprednate(Durezol) is a corticosteroid, approved for the treatment of post-operative ocular inflammation and pain.

体外活性

The difluprednate emulsion formulation begin by suspending DFBA in a variety of oils (castor, cottonseed, medium-chain fatty acid triglyceride, oleic, olive, peanut, and soybean). [1] Difluprednate ophthalmic emulsion's active metabolite, 6α,9-difluoroprednisolone 17-butyrate (DFB), has the lowest Ki value (611 nM) for the glucocorticoid receptor and is significantly more active than prednisolone, which has a Ki value of 3.4 nM. [2]

体内活性

Difluprednate emulsion is rapidly deacetylated in the aqueous humor to difluoroprednisolone butyrate (DFB) in rats and rabbits, the drug's active metabolite, which has a similar corticosteroid activity profile. Radio-labeled difluprednate is instilled in the right eyes of pigmented rabbits in a separate study examining DFBA excretion. Difluprednate (0.05% emulsion) results in higher aqueous humor concentrations than the suspension form in the eyes of rabbits. Difluprednate concentrations ≥0.01% shows a statistically significant inhibition of inflammation compared to saline in a rabbit model, with the anti-inflammatory response proceeding in a dose-dependent manner. Difluprednate suppresses uveitis in all three concentration (0.002%, 0.01%, and 0.05%) in a dose-dependent manner in rats, and difluprednate 0.05% shows statistically superior anti-inflammatory activity compared to Betamethasone (0.1%). [1]

Cas No.

23674-86-4

分子式

C27H34F2O7

分子量

508.559

别名

Myser;Epitopic;二氟孕甾丁酯;CM 9155

储存和溶解度

DMSO:93 mg/mL (182.9 mM)
Ethanol:24 mg/mL (47.2 mM)
H2O:<1 mgml
Powder: -20°C for 3 years
In solvent: -80°C for 2 years
 
 
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2024